Overview
Expert Insights on the Use of PCSK9 Inhibitors in Interventional Cardiology
PCSK9 roundtable discussion filmed in conjunction with C3 2018.
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This roundtable discussion includes a panel of three faculty experts, who review clinical evidence related to the use of PCSK9 inhibitors in managing hyperlipidemia. Utilizing supporting clinical data and real-world experience, the faculty discuss how gaps in patient care can be improved via increased recognition of high-risk patients, application of clinical trial data, and selection of therapies in complex patients.
This activity is intended for interventional cardiologists, cardiologists, vascular surgeons, cardiothoracic surgeons, technologists, and nurses involved in the management and treatment of patients with hyperlipidemia.
Treatment decisions for hyperlipidemia are increasingly challenging due to changing guidelines and a new class of therapies, the PCSK9 inhibitors. Further, clinicians must have competence in identifying high-risk patients who may require intensification or switching to a new therapy. Data from the cardiovascular outcomes trials with the PCSK9 inhibitors can assist in the identification of eligible at-risk patients. Interventional cardiologists require up-to-date knowledge of these new therapies and data since they are likely to encounter high-risk patients with hyperlipidemia.
Upon completion of this activity, participants will be able to:
• Outline considerations in the selection of LDL cholesterol targets across diverse patient populations
• Compare and contrast study designs, endpoints, and results of cardiovascular outcomes clinical trials of the PCSK9 inhibitors
• Identify high-risk patients who may be candidates for a PCSK9 inhibitor
• Formulate individualized treatment strategies for complex patients based on available evidence
• Discuss strategies to overcome barriers and ensure appropriate use of PCSK9 inhibitors in interventional cardiology settings
• Outline considerations in the selection of LDL cholesterol targets across diverse patient populations
• Compare and contrast study designs, endpoints, and results of cardiovascular outcomes clinical trials of the PCSK9 inhibitors
• Identify high-risk patients who may be candidates for a PCSK9 inhibitor
• Formulate individualized treatment strategies for complex patients based on available evidence
• Discuss strategies to overcome barriers and ensure appropriate use of PCSK9 inhibitors in interventional cardiology settings
Sponsored by the Academy for Continued Healthcare Learning (ACHL) and the Interventional Academy.
Supported by an educational grant from Amgen Inc.
Rajesh Dave, MD, FACC, FSCAI (Moderator)
Chief Medical Executive
Holy Spirit Cardiovascular Institute
Chairman, Department of Cardiology
Director, Cardiac Catheterization Laboratories
The Ortenzio Heart Center at Holy Spirit Hospital
Camp Hill, Pennsylvania
Chief Medical Executive
Holy Spirit Cardiovascular Institute
Chairman, Department of Cardiology
Director, Cardiac Catheterization Laboratories
The Ortenzio Heart Center at Holy Spirit Hospital
Camp Hill, Pennsylvania
Nihar Desai, MD, MPH
Assistant Professor of Medicine
Yale School of Medicine
New Haven, Connecticut
Robert Giugliano, MD, SM
Associate Professor of Medicine
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Raj Dave, MD, FACC, FSCAI
Board Member/Advisory Panel/Speakers Bureau: Abbott Vascular, Amgen, Aralez, Astellas, Boston Scientific Corporation, Bristol-Myers Squibb, Chiesi USA Inc, Pfizer, QT Vascular, Regeneron, and Sanofi-Aventis
Sources of Funding for Research: Abbott Vascular
Nihar Desai, MD, MPH
Honoraria: Amgen, Boehringer Ingelheim, Cytokinetics, and Relypsa
Research Support: Amgen, Boehringer Ingelheim, and Relypsa
Robert Giugliano, MD, SM
Consultant: Amarin, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, CVS Caremark, Daiichi Sankyo, GlaxoSmithKline, Lexicon, Merck, Portola, and Pfizer
Honoraria: Amgen, Daiichi Sankyo, and Merck
Research Support: Amgen
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Inclisiran
ACHL staff members, IA staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Katlyn Cooper at kcooper@achlcme.org.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and the Interventional Academy. ACHL is accredited by the ACCME to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.